Anhui Huaren Health Pharmaceutical 과거 수익 실적
과거 기준 확인 2/6
Anhui Huaren Health Pharmaceutical has been growing earnings at an average annual rate of 15.3%, while the Consumer Retailing industry saw earnings growing at 3.5% annually. Revenues have been growing at an average rate of 19.1% per year. Anhui Huaren Health Pharmaceutical's return on equity is 7.2%, and it has net margins of 3.1%.
주요 정보
15.3%
수익 성장률
11.7%
EPS 성장률
| Consumer Retailing 산업 성장 | 12.8% |
| 매출 성장률 | 19.1% |
| 자기자본 수익률 | 7.2% |
| 순이익 | 3.1% |
| 최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
These 4 Measures Indicate That Anhui Huaren Health Pharmaceutical (SZSE:301408) Is Using Debt Extensively
Aug 07
Anhui Huaren Health Pharmaceutical's (SZSE:301408) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 07Returns On Capital Signal Tricky Times Ahead For Anhui Huaren Health Pharmaceutical (SZSE:301408)
Mar 25수익 및 비용 분석
Anhui Huaren Health Pharmaceutical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 4,388 | 135 | 1,128 | 36 |
| 30 Jun 24 | 4,234 | 129 | 1,066 | 35 |
| 31 Mar 24 | 4,056 | 133 | 1,016 | 28 |
| 31 Dec 23 | 3,797 | 115 | 964 | 24 |
| 30 Sep 23 | 3,703 | 180 | 930 | 11 |
| 30 Jun 23 | 3,584 | 177 | 885 | 8 |
| 31 Mar 23 | 3,431 | 175 | 851 | 6 |
| 01 Jan 23 | 3,262 | 161 | 808 | 4 |
| 01 Jan 22 | 2,339 | 70 | 692 | 0 |
| 31 Dec 20 | 1,931 | 89 | 564 | 0 |
| 31 Dec 19 | 1,522 | 52 | 483 | 0 |
| 31 Dec 18 | 1,105 | 20 | 377 | 0 |
양질의 수익: 301408 has high quality earnings.
이익 마진 증가: 301408's current net profit margins (3.1%) are lower than last year (4.9%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 301408's earnings have grown by 15.3% per year over the past 5 years.
성장 가속화: 301408's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
수익 대 산업: 301408 had negative earnings growth (-25.4%) over the past year, making it difficult to compare to the Consumer Retailing industry average (6%).
자기자본 수익률
높은 ROE: 301408's Return on Equity (7.2%) is considered low.